Exact Mass: 419.002

Exact Mass Matches: 419.002

Found 41 metabolites which its exact mass value is equals to given mass value 419.002, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

S-(2,2-Dichloro-1-hydroxy)ethyl glutathione

(2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(2,2-dichloro-1-hydroxyethyl)sulfanyl]ethyl]-C-hydroxycarbonimidoyl}butanoic acid

C12H19Cl2N3O7S (419.0321)


This compound belongs to the family of Peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.

   
   

Methyl 5-(benzylcarbamoylamino)-3-(2,6-dichlorophenyl)-1,2-oxazole-4-carboxylate

Methyl 5-(benzylcarbamoylamino)-3-(2,6-dichlorophenyl)-1,2-oxazole-4-carboxylic acid

C19H15Cl2N3O4 (419.044)


   

4-Methylthio-3-butenyl glucosinolate

4-Methylthio-3-butenyl glucosinolate

C12H21NO9S3 (419.0378)


   

Luzonensol acetate

Luzonensol acetate

C17H25Br2O2 (419.0221)


   

Rosacyanin B

11- (3,4-Dihydroxyphenyl) -4,5,8-trihydroxy-2-oxo-2H-1,6-dioxa-10-oxoniabenzo [ cd ] pyrene

C22H11O9 (419.0403)


   

(E)-3-(13,13-dibromotrideca-1,12-dienyl)-2H-azirine-2-carboxylic acid|motualevic acid F

(E)-3-(13,13-dibromotrideca-1,12-dienyl)-2H-azirine-2-carboxylic acid|motualevic acid F

C16H23Br2NO2 (419.0095)


   
   
   

2-[(3-iodo-6-nitroindazol-1-yl)methoxy]ethyl-trimethylsilane

2-[(3-iodo-6-nitroindazol-1-yl)methoxy]ethyl-trimethylsilane

C13H18IN3O3Si (419.0162)


   

(+)-Clopidogrel bisulfate

(+)-Clopidogrel bisulfate

C16H18ClNO6S2 (419.0264)


   
   

1-(2,6-DICHLOROBENZYL)THIOETHYL-2-METHYL 5-PHENYLPYRROLE-3-CARBOXYLIC ACID

1-(2,6-DICHLOROBENZYL)THIOETHYL-2-METHYL 5-PHENYLPYRROLE-3-CARBOXYLIC ACID

C21H19Cl2NO2S (419.0513)


   

1-Butyl-3-Methylimidazolium Bis(Trifluoromesulfonyl)imide

1-Butyl-3-Methylimidazolium Bis(Trifluoromesulfonyl)imide

C10H15F6N3O4S2 (419.0408)


   

Ethyl 6-bromo-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate

Ethyl 6-bromo-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate

C19H18BrNO3S (419.0191)


   

0,11-DIMETHOXY-6-METHYL-5,6-DIHYDRO-4H-DIBENZO[DE,G]QUINOLINE

0,11-DIMETHOXY-6-METHYL-5,6-DIHYDRO-4H-DIBENZO[DE,G]QUINOLINE

C10H15F6N3O4S2 (419.0408)


   

2,3,4-Tri-O-acetyl-beta-L-arabinopyranosyl 2,2,2-Trichloroacetimidate

2,3,4-Tri-O-acetyl-beta-L-arabinopyranosyl 2,2,2-Trichloroacetimidate

C13H16Cl3NO8 (418.9941)


   

Clopidogrel bisulfate

Clopidogrel bisulfate

C16H18ClNO6S2 (419.0264)


C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent > C190801 - P2Y12 Inhibitor D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively[1]. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation[2].Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[5].

   

iron(3+),tribenzoate

iron(3+),tribenzoate

C21H15FeO6 (419.0218)


   

Ranirestat

Ranirestat

C17H11BrFN3O4 (418.9917)


C471 - Enzyme Inhibitor > C72880 - Aldose Reductase Inhibitor D004791 - Enzyme Inhibitors

   

(S)-5,5-Dioxo-9-((3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl)amino)-4,10-dihydrothieno(3,2-C)(1)benzothiepin-10-one

(S)-5,5-Dioxo-9-((3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl)amino)-4,10-dihydrothieno(3,2-C)(1)benzothiepin-10-one

C16H12F3NO5S2 (419.0109)


   

3-({4-[(5-Chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide

3-({4-[(5-Chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide

C17H14ClN5O4S (419.0455)


   

3-[2-Bromo-4-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-methylbenzonitrile

3-[2-Bromo-4-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-methylbenzonitrile

C20H14BrN5O (419.0382)


   

Plavix

Plavix

C16H18ClNO6S2 (419.0264)


D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors

   

Motualevic acid F

Motualevic acid F

C16H23Br2NO2 (419.0095)


A 2H-azirine that is 2H-azirene-2-carboxylic acid substituted by a 13,13-dibromotrideca-1,12-dien-1-yl group at position 3 (the 2R stereoisomer). It is isolated from the marine sponge Siliquariaspongia sp. and exhibits antibacterial properties.

   

Aurintricarboxylate

Aurintricarboxylate

C22H11O9-3 (419.0403)


   

[4-(7-Chloro-4-quinolinyl)-1-piperazinyl]-(3,4-dichlorophenyl)methanone

[4-(7-Chloro-4-quinolinyl)-1-piperazinyl]-(3,4-dichlorophenyl)methanone

C20H16Cl3N3O (419.0359)


   

[4-[[5-(2,4-Dichlorophenyl)-3-isoxazolyl]-oxomethyl]-1-piperazinyl]-(2-furanyl)methanone

[4-[[5-(2,4-Dichlorophenyl)-3-isoxazolyl]-oxomethyl]-1-piperazinyl]-(2-furanyl)methanone

C19H15Cl2N3O4 (419.044)


   

1-[[4-[(3,4-Dichlorophenyl)thio]-3-pyridinyl]sulfonyl]-3-propylurea

1-[[4-[(3,4-Dichlorophenyl)thio]-3-pyridinyl]sulfonyl]-3-propylurea

C15H15Cl2N3O3S2 (418.9932)


   

N(2)-(1-hydroxy-2-oxoethyl)-GMP

N(2)-(1-hydroxy-2-oxoethyl)-GMP

C12H14N5O10P-2 (419.0478)


   

1-S-[(1Z)-5-(methylsulfinyl)-N-(sulfooxy)pent-4-enimidoyl]-1-thio-beta-D-glucopyranose

1-S-[(1Z)-5-(methylsulfinyl)-N-(sulfooxy)pent-4-enimidoyl]-1-thio-beta-D-glucopyranose

C12H21NO9S3 (419.0378)


   

S-(2,2-Dichloro-1-hydroxy)ethyl glutathione

S-(2,2-Dichloro-1-hydroxy)ethyl glutathione

C12H19Cl2N3O7S (419.0321)


   

Glucoraphenin

Glucoraphenin

C12H21NO9S3 (419.0378)


A glucosinolic acid that consists of 1-thio-beta-D-glucopyranose attached to a 1-(methylsulfinyl)-5-[(sulfooxy)imino]pent-1-en-5-yl group at the anomeric sulfur.

   

(Rac)-PT2399

(Rac)-PT2399

C17H10F5NO4S (419.0251)


(Rac)-PT2399 (Compound 10e), the racemate of PT2399, acts as a potent and specific hypoxia-inducible factor 2a (HIF-2α) inhibitor with an IC50 of 0.01 μM[1].

   

Kobe2602

Kobe2602

C14H9F4N5O4S (419.0311)


Kobe2602 is a Ras-Raf interaction inhibitor. Kobe2602 inhibits the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki of 149 μM. Kobe2602 has antitumor activity[1].

   

PT2399

PT2399

C17H10F5NO4S (419.0251)


PT2399 is a potent and selective HIF-2α antagonist, which directly binds to HIF-2α PAS B domain with an IC50 of 6 nM. PT2399 displays potent antitumor activity in vivo[1][2][3].

   

SDZ 220-040

SDZ 220-040

C16H16Cl2NO6P (419.0092)


SDZ 220-040 is a competitive the mammalian NMDA receptor antagonist[1].

   

{[5-(methylsulfanyl)-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}pent-4-en-1-ylidene]amino}oxysulfonic acid

{[5-(methylsulfanyl)-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}pent-4-en-1-ylidene]amino}oxysulfonic acid

C12H21NO9S3 (419.0378)


   

7-(3,4-dihydroxyphenyl)-3,13,14-trihydroxy-10-oxo-6,9,19λ⁴-trioxapentacyclo[13.3.1.0⁵,¹⁸.0⁸,¹⁷.0¹¹,¹⁶]nonadeca-1(19),2,4,7,11,13,15,17-octaen-19-ylium

7-(3,4-dihydroxyphenyl)-3,13,14-trihydroxy-10-oxo-6,9,19λ⁴-trioxapentacyclo[13.3.1.0⁵,¹⁸.0⁸,¹⁷.0¹¹,¹⁶]nonadeca-1(19),2,4,7,11,13,15,17-octaen-19-ylium

[C22H11O9]+ (419.0403)


   

(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-{[(1z)-5-methanesulfinyl-1-(sulfoimino)pent-4-en-1-yl]sulfanyl}oxane-3,4,5-triol

(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-{[(1z)-5-methanesulfinyl-1-(sulfoimino)pent-4-en-1-yl]sulfanyl}oxane-3,4,5-triol

C12H21NO9S3 (419.0378)


   

[(z)-[(4e)-5-(methylsulfanyl)-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}pent-4-en-1-ylidene]amino]oxysulfonic acid

[(z)-[(4e)-5-(methylsulfanyl)-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}pent-4-en-1-ylidene]amino]oxysulfonic acid

C12H21NO9S3 (419.0378)